emraclidine
emraclidine: sourced relationships with 1 company · 4 clinical trials tracked.
emraclidine evidence translation
What we can confirm
4 tracked trials
What it means
What to watch
Prepared research question
How could emraclidine → CERE affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 1 study sponsors
Related indications
Study sponsors
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Cerevel Therapeutics Holdings, Inc. (CERE) | Phase 2 |
Clinical Trial Registry Records (4)
A Phase 1, Open-label, Single Dose, Crossover Study to Assess the Relative Bioavailability of Emraclidine Formulations in Healthy Adult Subjects
Primary endpoint: Number of Participants with Adverse Events (AEs)
A Phase 1, Randomized, Placebo-controlled Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Emraclidine Following Multiple Ascending Oral Doses in Healthy Elderly Subjects
Primary endpoint: Number of Participants Experiencing Adverse Events
An Adaptive Two-part Randomized, Double Blind, Placebo-controlled Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Emraclidine in Participants With Schizophrenia
Primary endpoint: Number of Participants with Adverse Events (AEs)
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia
Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
Frequently asked questions
Which companies have sourced relationships with emraclidine?
emraclidine has dated SEC/FDA relationship records for Cerevel Therapeutics Holdings, Inc..
How many clinical trials involve emraclidine?
BioSniper tracks 4 clinical trials involving emraclidine.